Regeneron Pharmaceuticals (REGN)
$493.32 5.43 (1.09%)
19:27 EDT REGN Stock Quote Delayed 20 Minutes
Previous Close $493.32
Market Cap 52.27B
PE Ratio 39.98
Volume (Avg. Vol.) 1.17M
Day's Range 485.04 - 503.26
52-Week Range 271.37 - 518.00
Dividend & Yield N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
- From InvestorPlace
- From the Web
Stocks slipped, but didn't plummet in the stock market today despite a horrendous jobs report that highlight the impact of Covid-19.
By David Moadel
April Fool's Day took many long-side traders by surprise. Thursday's big stock charts feature ones that showed resilience while the markets sank.
These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure. Buy them now.
Looking for hot stocks for 2020? These five stocks in particular have steadily outperformed the broader market during the coronavirus crisis.
Matt McCall is confident that, at least in the long term, the stimulus package will inject cash into the economy and help bring new highs.
3 Big Stock Charts for Tuesday: Abbott Laboratories, Johnson & Johnson, and Regeneron Pharmaceuticals
By David Moadel
Tuesday's big stock charts feature three companies that are contributing, in their own ways, to the fight against the coronavirus.
While coronavirus fears have killed the stock market this year, these nine best stocks for 2020 have bucked the trend.
These three will undoubtedly become stocks to buy. For right now they're critical stocks to watch as the market attempts to locate a bottom.
The coronavirus is an immediate catalyst for Regeneron stock but it's also too unreliable to provide buyers with lasting confidence.
Regeneron stock is one of the top names in the markets this year “thanks” to the coronavirus. But microbial threats down the line ensure that REGN is no flash in the pan.
At one point, the Dow Jones slid 1,000 and the Nasdaq was down more than 4% thanks to the coronavirus. Here's the stock market today.
The SPY and QQQ were our focus, while Microsoft and Regeneron were our other top stock trades for Tuesday.
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
Thursday's big stock charts detail the hopes for 3 stocks trying to recover from multi-year lows.
Regeneron Pharmaceuticals (REGN) earnings for the biotechnology company's third quarter of 2019 have REGN stock soaring on Tuesday.
Cara stock is up ahead of its presentations at Kidney Week 2019. Unless it reports bad news, Cara Therapeutics looks ready to run.
Of the undervalued stocks that Goldman Sachs recently thrust into the spotlight, these three are the most promising stocks to buy. Here's what you need to know about each.
From Talk Markets
From Real Money
Navellier RatingsPowered by Portfolio Grader